Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0292 · 4 trials · 3 indications
To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA
To assess the safety and tolerability of AZD0292 following IV administration of single ascending doses to healthy Japanese adult participants.
The safety and tolerability of AZD0292 following IV administration of single ascending doses to healthy adult participants will be assessed.
The safety and tolerability of AZD0292 following IV administration of single ascending doses to healthy adult participants will be assessed.
| Arm | Type | Description |
|---|---|---|
| AZD0292 | EXPERIMENTAL | AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered starting on Day 1, subsequent administrations per schedule of assessments. |
| High-dose | EXPERIMENTAL | High-Dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Low-dose | EXPERIMENTAL | Low-dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| AZD0292 Dose Level 1 | EXPERIMENTAL | Participants will receive AZD0292 (dose level 1) or matching placebo on Day 1. |
| AZD0292 Dose Level 2 | EXPERIMENTAL | Participants will receive AZD0292 (dose level 2) or matching placebo on Day 1. |
| AZD0292 Dose 1 | EXPERIMENTAL | Participants will receive single dose of AZD0292 dose 1 as IV infusion on Day 1. |
| AZD0292 Dose 2 | EXPERIMENTAL | Participants will receive single dose of AZD0292 dose 2 as IV infusion on Day 1. |
| AZD0292 Dose 3 | EXPERIMENTAL | Participants will receive single dose of AZD0292 dose 3 as IV infusion on Day 1. |
| Name | Type | Description |
|---|---|---|
| AZD0292 | DRUG | AZD0292 administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments. |
| Placebo | OTHER | Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments. |
Inclusion Criteria: * Participant must be ≥ 18 years of age at the time of signing the informed consent/assent. * Weight ≥ 35 kg. * Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years i...
AZD0292 is an investigational monoclonal antibody being developed for bronchiectasis with chronic Pseudomonas aeruginosa colonization. It is also studied in healthy participants for safety and pharmacokinetic assessments. The drug is administered intravenously and is currently in Phase 2 clinical development for the bronchiectasis indication.
AZD0292 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the safety, efficacy, and pharmacokinetics of AZD0292 in patients with bronchiectasis and chronic Pseudomonas aeruginosa colonization.
AZD0292 is in Phase 2 clinical development for bronchiectasis with chronic Pseudomonas aeruginosa colonization. The drug is investigational and not yet approved by regulatory authorities. AstraZeneca is currently recruiting participants for Phase 2 trials evaluating its efficacy and safety in this patient population.
AZD0292 is being studied in several clinical trials. NCT07088926 is a Phase 2 study in participants aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa colonization. NCT07774403 is a Phase 2 study in Chinese participants with the same condition. NCT06311760 and NCT07222254 are completed Phase 1 studies in healthy participants.
AZD0292 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for bronchiectasis with chronic Pseudomonas aeruginosa colonization. The drug is still in clinical development and has not yet received regulatory approval for any indication.